The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL
Authors
Keywords
-
Journal
Cancers
Volume 9, Issue 12, Pages 121
Publisher
MDPI AG
Online
2017-09-11
DOI
10.3390/cancers9090121
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
- (2017) Anella Yahiaoui et al. PLoS One
- Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
- (2016) Sarah K. Tasian et al. BLOOD
- Discovery of Orally Efficacious Phosphoinositide 3-Kinase δ Inhibitors with Improved Metabolic Stability
- (2016) Leena Patel et al. JOURNAL OF MEDICINAL CHEMISTRY
- Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
- (2016) S Eldfors et al. LEUKEMIA
- Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 , for relapsed/refractory chronic lymphocytic leukemia
- (2014) J. R. Brown et al. BLOOD
- PI3Kδ Inhibition Hits a Sensitive Spot in B Cell Malignancies
- (2014) Bart Vanhaesebroeck et al. CANCER CELL
- Idelalisib—targeting PI3Kδ in patients with B-cell malignancies
- (2014) Jan A. Burger et al. Nature Reviews Clinical Oncology
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Integrin Alpha4 in Drug Resistance of Leukemia
- (2014) Stephanie Shishido et al. Frontiers in Oncology
- PKB/Akt-Dependent Regulation of Cell Motility
- (2013) G. Xue et al. JNCI-Journal of the National Cancer Institute
- Relapsed childhood acute lymphoblastic leukaemia
- (2013) Deepa Bhojwani et al. LANCET ONCOLOGY
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells
- (2013) Stefania Fiorcari et al. PLoS One
- Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group
- (2012) Stephen P. Hunger et al. JOURNAL OF CLINICAL ONCOLOGY
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
- (2009) Pasi A. Jänne et al. NATURE REVIEWS DRUG DISCOVERY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started